PCM
VIR icon

Prelude Capital Management’s Vir Biotechnology VIR Stock Holding History

Prelude Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,000
Closed -$108K – 1573
2025
Q3 		$108K Buy
+19,000
New +$97.2K 0.01% 1046
2025
Q1 		– Sell
-16,400
Closed -$120K – 1550
2024
Q4 		$120K Sell
16,400
-5,886
-26% -$46.4K 0.01% 1075
2024
Q3 		$167K Buy
22,286
+10,632
+91% +$92.3K 0.01% 1095
2024
Q2 		$104K Sell
11,654
-2,524
-18% -$24.2K 0.01% 1096
2024
Q1 		$144K Sell
14,178
-2,985
-17% -$30.4K 0.01% 1166
2023
Q4 		$173K Buy
17,163
+4,203
+32% +$38.4K 0.01% 973
2023
Q3 		$121K Buy
+12,960
New +$185K 0.01% 969
2022
Q2 		– Sell
-8,684
Closed -$223K – 2082
2022
Q1 		$223K Buy
+8,684
New +$258K 0.01% 1211
2020
Q4 		– Sell
-1,532
Closed -$53K – 2041
2020
Q3 		$53K Sell
1,532
-1,668
-52% -$71.8K ﹤0.01% 1106
2020
Q2 		$131K Buy
+3,200
New +$107K 0.01% 861

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Prelude Capital Management's VIR Position: Q4 2025 in Review

Prelude Capital Management sold out of Vir Biotechnology (VIR) in Q4 2025, closing a stake of 19,000 shares — an estimated $108K sold.

Prelude Capital Management first reported a position in VIR in Q2 2020 and held it in 10 quarters. The position peaked at $223K in Q1 2022. 218 funds tracked by Wall St. Rank hold VIR as of Q4 2025.

  • Prelude Capital Management reported no remaining Vir Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Prelude Capital Management sold 19,000 Vir Biotechnology shares in Q4 2025, an estimated $108K.
  • Prelude Capital Management first reported a position in Vir Biotechnology in Q2 2020 and held it in 10 quarters.
  • Prelude Capital Management's Vir Biotechnology position peaked at $223K in Q1 2022.
  • 218 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.